• Isradipine (Dynacirc): A Calcium Attribution Guide

  2026-08-26

  Isradipine and Dynacirc are examined here through a channel-attribution framework rather than a conventional product workflow. Learn how L-type pharmacology, neuronal calcium-channel heterogeneity, and assay controls shape rigorous hypertension and neuroprotection research.

• BFH772 (VEGFR2 inhibitor): Workflow Guide

  2026-08-26

  BFH772 is a selective VEGFR2 kinase inhibitor for experiments that require controlled modulation of VEGFR2-mediated angiogenic signaling. Its organic-solvent solubility and water insolubility make it suitable for biochemical, cellular, and tumor-model workflows with validated vehicle controls, but unsuitable for protocols requiring aqueous dosing or broad-spectrum kinase inhibition.

• Angiotensin I: Applied Assay Workflows

  2026-08-25

  Turn Angiotensin I into a controllable probe for renin-angiotensin system research, ACE activity studies, antihypertensive drug screening, and neuroendocrine models. This guide combines peptide handling, conversion-assay design, fluorescence-data safeguards, and troubleshooting for more interpretable results.

• SepM Mutations and S. mutans–S. gordonii Inhibition

  2026-08-24

  Liu et al. linked recurrent sepM missense mutations in clinical Streptococcus mutans isolates with stronger inhibition of Streptococcus gordonii and investigated how selected substitutions alter SepM–CSP-21 binding. The study connects bacterial genotype, ComDE signaling, protein structure, and pH-dependent ligand affinity, while also defining important limits for interpreting these findings in oral biofilm biology.

• Acetylcysteine: Mechanism and Research Use

  2026-08-24

  Acetylcysteine, also called N-acetyl-L-cysteine or NAC, is a cysteine source for glutathione biosynthesis and a direct thiol-based redox reagent. Its research value spans oxidative stress pathway modulation, hepatic protection research, respiratory disease models, and Huntington’s disease research, but experimental effects remain concentration-, cell-, and model-dependent.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-08-23

  A 2026 study identifies an O-GlcNAc–HUWE1–TfR1 signaling axis that connects trophoblast ferroptosis, iron uptake, and syncytialization defects in preeclampsia. Its combination of O-GlcNAc modification proteomics, mechanistic ubiquitination studies, trophoblast experiments, and mouse validation provides a framework for studying placental stress while highlighting important limits for translation.

• Genetically Engineered Mouse Models of Mesothelioma

  2026-08-22

  Kadariya and colleagues present a protocol-centered framework for modeling malignant mesothelioma with genetically engineered mice carrying germline or conditional Bap1 alterations, with or without asbestos exposure. The review clarifies how these autochthonous models reproduce important genetic, inflammatory, and immune features of human disease and can support therapeutic, chemoprevention, and cancer-interception studies.

• Tacrine hydrochloride hydrate in AD Assays

  2026-08-21

  Tacrine hydrochloride hydrate, also known as Tetrahydroaminacrine, provides a practical benchmark for cholinesterase inhibition, cholinergic rescue, and neuroprotection experiments. This guide connects assay-ready preparation with metabolism-aware study design, helping researchers distinguish true biological activity from solvent, stability, or cytotoxicity artifacts.

• Toxoplasma Cyst Wall Regulation: Silva 2023

  2026-08-20

  Toby Silva’s 2023 University of Edinburgh thesis investigates how phosphorylation and the phosphatase PPM3C may regulate Toxoplasma gondii cyst-wall biology through the secreted protein GRA2 and the cyst-wall protein CST1. The work provides a useful experimental framework and preliminary evidence that PPM3C affects CST1 localization, while also revealing important limitations of genetic markers and antibody strategies during bradyzoite differentiation.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-08-20

  Anlotinib hydrochloride enables a coordinated angiogenesis workflow that connects endothelial migration, tube formation, receptor phosphorylation, and ERK signaling. Its multi-target profile supports mechanism-led cancer research while providing practical options for assay comparison, optimization, and troubleshooting.

• ML365 and NLRP3 in Postoperative Cognitive Impairment

  2026-08-19

  A 2024 Brain Research study found that ML365 pretreatment reduced postoperative cognitive impairment in aged mice after exploratory laparotomy, alongside lower hippocampal NLRP3 inflammasome signaling and oxidative stress. The work offers pharmacological evidence connecting two-pore potassium channel inhibition with postoperative neuroinflammation, while leaving direct target engagement and clinical translation unresolved.

• Dual Enzyme-Responsive Peptides for Cancer Selectivity

  2026-08-19

  The 2026 Biomacromolecules study presents a zwitterionic peptide amphiphile that uses sequential MMP-7-mediated disassembly and cathepsin B-triggered intralysosomal assembly to selectively damage cancer cells. Its reported cancer selectivity index of 64.1 and activity in an HT-29 xenograft model indicate a promising, but still preclinical, strategy for enzyme-gated peptide therapeutics.

• Arsenic, MMP-2/MMP-9, and BBB Cognitive Injury

  2026-08-18

  This study identifies a mechanistic link between chronic sodium arsenite exposure, MMP-2/MMP-9-associated blood-brain barrier disruption, hippocampal neuronal apoptosis, and impaired learning and memory in male mice. Doxycycline hyclate intervention preserved tight-junction features and improved behavioral outcomes, supporting MMP-2 and MMP-9 as experimentally relevant targets in arsenic neurotoxicity.

• KPT-330 (Selinexor) Workflow for CRM1 Studies

  2026-08-17

  Build reproducible CRM1-inhibition assays with KPT-330 (Selinexor), from DMSO stock preparation through viability, apoptosis, ROS, and DNA-damage readouts. The workflow also translates recent DLBCL combination findings into practical platinum-sensitivity experiments while separating literature evidence from starting-point optimization.

• RIPA Lysis Buffer Strong: Practical Workflow

  2026-08-17

  RIPA Lysis Buffer (Strong, without inhibitors) provides detergent-based extraction for animal cells and tissues when robust protein solubilization and customized inhibitor selection are required. It is appropriate for Western blotting, immunoprecipitation, ELISA, and protein kinase workflows, but should be evaluated carefully when native protein complexes, enzyme activity, or inhibitor-free conditions are essential.

455 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page